Skip to main content
1776 search results for:

Ramucirumab 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. Open Access 15-04-2024 | Ramucirumab | Online First

    Real-World Effectiveness and Safety of Ramucirumab as a Second-Line Treatment for Patients with Unresectable Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in Japan and South Korea: A Systematic Literature Review

    Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer death worldwide, with 1.09 million new cases and 0.77 million deaths in 2020 [ 1 ]. There is a heavy burden of gastric cancer in Eastern Asia, which has the …

  2. 11-03-2024 | Ramucirumab | Online First

    Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients

    Lung cancer has a poor prognosis, and the number of patients with lung cancer is increasing worldwide [ 1 ]. In particular, the number of older patients with lung cancer is increasing owing to the aging of the population and the extension of …

  3. 01-01-2024 | Ramucirumab | News

    Ramucirumab

    Gastrocolic fistula
  4. Open Access 01-12-2023 | Ramucirumab | OriginalPaper

    Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415)

    Gastro-esophageal adenocarcinoma (GEA) is the fifth most common cancer worldwide, causing over one million new cases (1,033,701) each year and is the third-leading cause of cancer death (about 782,685 deaths and 8.2% of total in 2018) [ 1 ].

  5. Open Access 01-12-2023 | NSCLC | OriginalPaper

    A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer

    According to GLOBOCAN 2020, lung cancer is the second most common cancer and the leading cause of cancer-related death worldwide [ 1 ]. Non–small cell lung cancer (NSCLC) accounts for nearly 85% of primary lung cancer cases. NSCLC ‘tends to …

  6. 01-01-2023 | Metastasis | News

    Ramucirumab

    Gastrointestinal perforations: case report
  7. 04-09-2023 | Ramucirumab | OriginalPaper

    Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer–single institutional experience

    Gastric cancer is the fourth leading cause of cancer death in the world and the fifth most common malignant tumor [ 1 ]. Combination regimens including a fluoropyrimidine and a platinum agent plus nivolumab for HER2-negative cases or trastuzumab …

  8. 01-06-2023 | Ramucirumab | OriginalPaper

    Impact of prior bevacizumab therapy on the incidence of ramucirumab-induced proteinuria in colorectal cancer: a multi-institutional cohort study

    Colorectal cancer (CRC) is the second leading cause of cancer-related deaths worldwide, and the 5-year relative survival rate of patients with metastatic disease is 15% [ 1 , 2 ]. In the past two decades, remarkable progress has been made in the …

  9. 01-06-2022 | Premedication | News

    Ramucirumab

    Infusion-related reaction: 2 case reports
  10. Open Access 27-04-2023 | Neutropenia | OriginalPaper

    Post-Marketing Safety Study of Ramucirumab Plus FOLFIRI: Analysis of Age and Initial Dose of Irinotecan in Patients with Metastatic Colorectal Cancer

    The standard of care for metastatic colorectal cancer (mCRC) is chemotherapy, either in combination or as single agents. Irinotecan is one of the key agents to be approved for the systemic treatment of mCRC; however, it is frequently accompanied …

  11. 21-11-2022 | Gastric Cancer | OriginalPaper

    Treatment efficacy of ramucirumab-containing chemotherapy in patients with alpha-fetoprotein producing gastric cancer

    α-Fetoprotein (AFP) is an oncofetal protein, which has been thought analog of serum albumin, and AFP is normally produced in the fetal liver and yolk sac during the gestational period [ 1 ]. Because AFP is rarely produced in human adults and the …

  12. Open Access 17-06-2023 | Erlotinib | OriginalPaper

    Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study

    In 2020, lung cancer was the second most common cancer worldwide, with approximately 2.21 million new cases, and was associated with the highest number of cancer deaths at 1.80 million [ 1 ]. In Taiwan, lung cancer has the highest mortality rate of …

  13. Open Access 01-04-2022 | Gastric Cancer | OriginalPaper

    Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study)

    Fluoropyrimidine plus platinum is the recommended standard first-line chemotherapy for unresectable advanced or recurrent gastric cancer (AGC) according to several guidelines [ 1 – 3 ]. The RAINBOW trial [ 4 ] demonstrated the superiority of weekly …

  14. Open Access 01-12-2023 | Ramucirumab | OriginalPaper

    Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study

    Gastric cancer (GC) is one of the most common cancers with the fifth highest incidence and fourth highest mortality worldwide [ 1 ]. In Japan, it accounts for the second highest morbidity and third highest mortality [ 2 ]. Taxanes (paclitaxel (PTX) …

  15. 15-04-2023 | Neutropenia | OriginalPaper

    A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09)

    Taxanes inhibit the disassembly of microtubules, thereby causing cell death by disrupting the normal microtubule dynamics required for cell division and vital interphase processes [ 1 – 3 ]. Solvent-based (sb) paclitaxel (PTX) is an important drug …

  16. 17-07-2023 | Ramucirumab | OriginalPaper

    Effect of massive ascites on ramucirumab pharmacokinetics in patients with gastrointestinal cancers: a population pharmacokinetic analysis

    Ramucirumab, a fully human immunoglobulin G (IgG) 1 monoclonal antibody that targets vascular endothelial growth factor receptor 2, is used to treat a range of cancers, including gastrointestinal cancers [ 1 – 4 ]. As a valuable antiangiogenic …

  17. 01-06-2023 | Ramucirumab | News

    Ramucirumab

    Treatment failure: case report
  18. 01-09-2021 | Gastric Cancer | News

    Ramucirumab

    Pyogenic granuloma: 2 case reports
  19. Open Access 01-12-2023 | Ramucirumab | OriginalPaper

    Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G)

    Gastric cancer (GC) is the fifth most common and fourth most deadly cancer worldwide [ 1 ]. It is more common in East Asia than in the Western countries. It is difficult to cure in patients with recurrent or unresectable GC or esophagogastric …

  20. Open Access 01-12-2022 | Gastric Cancer | OriginalPaper

    Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S − 1 therapy

    Gastric cancer (GC) is the fifth most common cancer site and the third leading cause of cancer-related deaths worldwide [ 1 ]. Although the curative treatment of locally advanced GC is surgery, some cases experience relapse even after R0 resection …

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.